Compare Citius Pharmaceuticals Inc (CTXR) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Global X NASDAQ 100 Covered Call ETF trades at $18.32. The key difference: Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | QYLD | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $1.82 | $18.52 |
52-Week Low | $0.53 | $16.46 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
QYLD trades at $18.15, down 1.68% on the day, with technical indicators showing a neutral overall signal. The ETF's covered call strategy generates high monthly distributions but has historically lagged the Nasdaq-100's total return, with recent news highlighting NAV erosion despite consistent dividend payouts. Moving averages suggest a bullish trend while oscillators remain neutral, with all key support and resistance levels clustered around $18.
The outlook remains cautious as QYLD's high yield comes at the cost of capital appreciation potential. While attractive for income-focused investors, the strategy underperforms in strong bull markets. Key risks include capped upside and competitive pressure from lower-fee alternatives like GPIQ, requiring investors to prioritize income generation over growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
